Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q3 2021 · 10-Q
Revenue$5.11M$5.11M−8.2% vs Q3 2020 Net Income-$40.00K-$40.00KN/M vs Q3 2020 EPS Diluted$0.00$0.00N/M vs Q3 2020 Gross Profit$2,358,000−4.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,568,000N/M Free Cash Flowderived-$1,568,000N/M Margins · derivedGross margin46.2%+2.0 pt vs Q3 2020
Operating margin-58.4%−1.7 pt vs Q3 2020
Net margin-0.8%+56.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end